Compare WTO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTO | EVAX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 31.9M |
| IPO Year | 2019 | 2020 |
| Metric | WTO | EVAX |
|---|---|---|
| Price | $2.54 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 25.9K | ★ 29.9K |
| Earning Date | 08-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $1.20 |
| 52 Week High | $4.50 | $12.15 |
| Indicator | WTO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 49.43 |
| Support Level | $0.79 | $2.70 |
| Resistance Level | $3.41 | $4.64 |
| Average True Range (ATR) | 0.29 | 0.33 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 16.83 | 47.38 |
UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.